<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR80">
 <label>80.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Zhong</surname>
    <given-names>W-Z</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study</article-title>
  <source>Lancet Oncol</source>
  <year>2018</year>
  <volume>19</volume>
  <issue>1</issue>
  <fpage>139</fpage>
  <lpage>148</lpage>
  <pub-id pub-id-type="doi">10.1016/S1470-2045(17)30729-5</pub-id>
  <?supplied-pmid 29174310?>
  <pub-id pub-id-type="pmid">29174310</pub-id>
 </element-citation>
</ref>
